Legal Representation
Attorney
Christopher D. Olszyk, Jr.
USPTO Deadlines
Next Deadline
109 days remaining
Statement of Use Due - Extension 3 Granted
Due Date
December 05, 2025
Extension Available
Until December 05, 2024
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 5, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jun 5, 2025 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jun 5, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 3, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 5, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Dec 5, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Dec 4, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 13, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 4, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jun 4, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jun 4, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 5, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 10, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 10, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 20, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 1, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 31, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 10, 2023 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Aug 9, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 13, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for use in the treatment of seizures, bipolar disorders, depression, amyotrophic lateral sclerosis, migraines, Parkinson's disease, neurofibromatosis, chronic obstructive pulmonary disease, and ophthalmology-related disorders including dry eye and glaucoma; Pharmaceutical preparations for the prevention and treatment of central nervous system disorders, neurological diseases and disorders, neurodegenerative disorders, depression and ophthalmology-related disorders including dry eye and glaucoma; Pharmaceutical preparations for the treatment of seizures in epilepsy, mood changes in bipolar disorders and depression, reduction in symptoms associated with amyotrophic lateral sclerosis, migraines, Parkinson's disease, and ophthalmology-related disorders including dry eye and glaucoma, chronic obstructive pulmonary disease, and lesion reduction in neurofibromatosis, each administered via drug delivery agents in the form of liquids, extended-release oral solids, inhalation, liquid nasal sprays, powder nasal sprays, and topical formulations that facilitate the delivery of pharmaceutical preparations
Additional Information
Design Mark
The mark consists of an image of a triangle inside a square located above the wording "AUCTA" stacked above the term "PHARMACEUTICALS".
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMACEUTICALS"